Nabla Bio vs Superluminal Medicines (2026)
These two go after the same targets from opposite directions. Both focus on G protein coupled receptors, a family where much of the receptor space is still undrugged, but they design different kinds of molecule for them. Nabla Bio designs antibodies, large biologics that bind the receptor from outside the cell, using its JAM generative system and publishing its hit rates target by target. Superluminal Medicines designs small molecules against the same receptors, the older and harder computational problem on this class, and has raised substantially, with a Series B in September 2026 and investors including Eli Lilly and Nvidia. The choice is really about modality, not vendor. Nabla is the one when an antibody against a membrane receptor is the goal. Superluminal is the one when a small molecule drug against a GPCR is what a program needs.
- Antibody design against membrane receptors, delivered through discovery collaborations.
- Hit rates published target by target, including the targets that produced nothing.
- A fit for programs that need a biologic against a GPCR or ion channel.
- Small molecule design against GPCRs, a different modality for the same receptor family.
- A well funded company with a 2026 Series B and investors including Eli Lilly and Nvidia.
- A fit for programs that need an orally available small molecule rather than an antibody.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Nabla Bio and Superluminal Medicines are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Nabla Bio | Superluminal Medicines |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2021 | 2023 |
| Headquarters | Cambridge, Massachusetts, United States | Boston, Massachusetts, United States |
| Website | nabla.bio | superluminalrx.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Nabla Bio its top capability grade on AI Centrality and AI Governance and Bias Disclosure. Set against Superluminal Medicines, Nabla Bio grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
The AI Health Index records no top capability grade for Superluminal Medicines on any axis it scores. Set against Nabla Bio, Superluminal Medicines does not grade higher on any scored axis, though the two are level on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
Questions buyers ask
Should we choose Nabla Bio or Superluminal Medicines?
The AI Health Index grades Nabla Bio higher than Superluminal Medicines on every axis that separates them, several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Superluminal Medicines does not grade higher on any scored axis.
Where do Nabla Bio and Superluminal Medicines differ most?
The widest separation the AI Health Index records between Nabla Bio and Superluminal Medicines is on AI Governance and Bias Disclosure, where Nabla Bio grades A and Superluminal Medicines grades D. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Nabla Bio and Superluminal Medicines grade the same?
The AI Health Index grades Nabla Bio and Superluminal Medicines the same on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Nabla Bio and Superluminal Medicines not disclosed?
At the last review, at least one of Nabla Bio and Superluminal Medicines published thin or absent detail on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed in October 2026. Neither publishes a price, and they are not direct substitutes: one makes antibodies, the other makes small molecules, for overlapping targets.
Ask both which receptors they have produced active molecules against, and how each reports the programs that did not progress.